Neumora Therapeutics, Inc. (NMRA) stock
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.43−0.00 (-0.95%)
Close on Nov 13, 2026Market cap $80.59MP/E –Yield –
Neumora Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Neumora Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $153.07M, down 22.5% year over year. For fiscal 2025 it was $176.07M, down 12.4% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $176.07M | -12.4% |
| FY2024 | Dec 31, 2024 | $200.93M | +40.8% |
| FY2023 | Dec 31, 2023 | $142.72M | +55.6% |
| FY2022 | Dec 31, 2022 | $91.75M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $29.28M | -24.4% |
| Q1 FY2026 | Mar 31, 2026 | $38.60M | -26.0% |
| Q4 FY2025 | Dec 31, 2025 | $44.67M | -2.7% |
| Q3 FY2025 | Sep 30, 2025 | $40.52M | -33.2% |
| Q2 FY2025 | Jun 30, 2025 | $38.72M | -20.4% |
| Q1 FY2025 | Mar 31, 2025 | $52.15M | +14.0% |
| Q4 FY2024 | Dec 31, 2024 | $45.91M | +18.1% |
| Q3 FY2024 | Sep 30, 2024 | $60.63M | +45.7% |
| Q2 FY2024 | Jun 30, 2024 | $48.63M | +48.4% |
| Q1 FY2024 | Mar 31, 2024 | $45.76M | +55.2% |
| Q4 FY2023 | Dec 31, 2023 | $38.86M | +65.2% |
| Q3 FY2023 | Sep 30, 2023 | $41.60M | +84.5% |
| Q2 FY2023 | Jun 30, 2023 | $32.77M | – |
| Q1 FY2023 | Mar 31, 2023 | $29.49M | – |
| Q4 FY2022 | Dec 31, 2022 | $23.52M | – |
| Q3 FY2022 | Sep 30, 2022 | $22.55M | – |
See a number that looks wrong?